Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Rhea-AI Summary

Protagonist Therapeutics (NASDAQ:PTGX) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY, scheduled for September 9-11, 2024. The company's President and CEO, Dinesh V. Patel, Ph.D., will engage in a fireside chat on Tuesday, September 10 at 1:30 P.M. ET.

The fireside chat will be accessible via webcast, providing an opportunity for investors and interested parties to gain insights into Protagonist's developments and strategies. Additionally, the company will be available for one-on-one meetings during the conference, offering a more personalized interaction for attendees.

This participation underscores Protagonist's commitment to engaging with the investment community and sharing updates on its progress in the biotechnology sector.

NEWARK, CA / ACCESSWIRE / September 3, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.

H.C. Wainwright 26th Annual Global Investment Conference - September 9-11, 2024

Format: Fireside Chat
Day/Time: Tuesday, September 10 at 1:30 P.M. ET
Webcast: https://journey.ct.events/view/6728cec4-cfc2-42c8-bb71-746abcedbd33

If you are interested in meeting with the Protagonist team during the conference, please reach out to your H.C. Wainwright representative.

About Protagonist

Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced Phase 3 stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and Johnson & Johnson (JNJ) scientists jointly discovered JNJ-2113 as part of Protagonist's Interleukin-23 receptor (IL-23R) antagonist collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. JNJ-2113 is currently being pursued in five Phase 3 studies in psoriasis, and a Phase 2b study in ulcerative colitis. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program for polycythemia vera (PV). The randomized portion of the Phase 2 REVIVE study has been successfully completed, and results were published in The New England Journal of Medicine in February 2024. The open-label extension (OLE) component of REVIVE has also been completed and is followed by an additional 2-year long-term extension (LTE) THRIVE study. Enrollment has been completed in the global Phase 3 VERIFY study of rusfertide in polycythemia vera. Rusfertide is being co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda announced in January 2024.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.

Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com

Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
virginiaamann@ententeinc.com

SOURCE: Protagonist Therapeutics, Inc.

View the original press release on accesswire.com

FAQ

When is Protagonist Therapeutics (PTGX) participating in the H.C. Wainwright Global Investment Conference?

Protagonist Therapeutics (PTGX) is participating in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, with a fireside chat scheduled for Tuesday, September 10 at 1:30 P.M. ET.

Who will represent Protagonist Therapeutics (PTGX) at the H.C. Wainwright conference?

Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist Therapeutics, will represent the company at the H.C. Wainwright conference.

How can investors access Protagonist Therapeutics' (PTGX) presentation at the H.C. Wainwright conference?

Investors can access Protagonist Therapeutics' (PTGX) fireside chat presentation via webcast at https://journey.ct.events/view/6728cec4-cfc2-42c8-bb71-746abcedbd33.

Will Protagonist Therapeutics (PTGX) be available for individual meetings during the conference?

Yes, Protagonist Therapeutics (PTGX) will be available for one-on-one meetings during the H.C. Wainwright conference. Interested parties should contact their H.C. Wainwright representative to arrange a meeting.